Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Busse

Allergy & Immunology Madison, WI Medical Doctor

NPI 1881661486 CMS profile 1128649

5510 S Hill Dr, Madison, WI 53705

Open in the dashboard

General payments

$928,186

517 records reported · program years 2019–2025

Research payments

$86,756

Paid to them · 153 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Busse of Madison, WI is reported in the CMS Open Payments database as having received $928,186 across 517 general payments and $86,756 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46,738 33
2025 Research $4,698 10
2024 General $98,645 57
2024 Research $4,000 7
2023 General $116,107 70
2023 Research $9,339 23
2022 General $84,796 36
2022 Research $17,820 42
2021 General $158,718 85
2021 Research $24,412 27
2020 General $133,335 53
2020 Research $13,834 16
2019 General $289,847 183
2019 Research $12,652 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Busse
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to William Busse were reported at $46,738. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year William Busse Allergy & Immunology median Middle half National median
2019 $289,847 $378 $115–$1,178 $163
2020 $133,335 $303 $75–$1,581 $114
2021 $158,718 $407 $122–$1,475 $132
2022 $84,796 $357 $120–$1,340 $149
2023 $116,107 $445 $124–$1,536 $160
2024 $98,645 $541 $129–$1,763 $164
2025 $46,738 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $486,546 233 payments
  2. Regeneron Healthcare Solutions, Inc. $168,940 133 payments
  3. Sanofi-Aventis U.S. LLC $105,969 36 payments
  4. GlaxoSmithKline, LLC. $70,248 37 payments
  5. Regeneron Pharmaceuticals, Inc. $47,453 41 payments
  6. F. Hoffmann-La Roche AG $13,777 4 payments
  7. Novartis Pharmaceuticals Corporation $7,324 8 payments
  8. Sanofi US Services Inc. $7,301 4 payments
  9. Genentech USA, Inc. $4,711 5 payments
  10. Incyte Corporation $3,610 4 payments
  11. Other $12,308 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $500,420 110 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $276,131 97 payments
  3. Travel and Lodging $143,285 199 payments
  4. Food and Beverage $8,321 110 payments
  5. Education $29 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $261,159 83 payments
  2. DUPIXENT Immunology $130,415 66 payments
  3. DUPIXENT Inflammation And Immunology $91,323 76 payments
  4. NO PRODUCT DISCUSSED $42,940 22 payments
  5. NUCALA Respiratory $31,717 17 payments
  6. Xolair Immunology $16,402 6 payments
  7. TRELEGY ELLIPTA $15,009 11 payments
  8. NUCALA Immunology $7,412 3 payments
  9. XOLAIR Respiratory $7,324 8 payments
  10. DUPIXENT Immunology And Inflammation $4,287 3 payments
  11. Other $6,785 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genzyme Corporation $42,000 100 payments
  2. Sanofi-Aventis U.S. LLC $16,821 38 payments
  3. F. Hoffmann-La Roche AG $11,383 5 payments
  4. Novartis Pharma AG $9,346 1 payment
  5. Genentech, Inc. $3,848 4 payments
  6. Regeneron Pharmaceuticals, Inc. $3,358 5 payments

Records

670 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record